Urology reports (St. - Petersburg)Urology reports (St. - Petersburg)2225-90742687-1416Eco-Vector618910.17816/uroved7110-14Research ArticleThe use of doppler ultrasound for differential diagnosis of prostate diseasesKurnakovAnton M<p>Postgraduate, Urology Department</p>kurnakov_a@mail.ruBorovetsSergey Yu<p>doctor of medical science, professor. Department of Urology</p>sborovets@mail.ruAl-ShukriSalman Kh<p>doctor of medical science, professor, head of the department. Department of Urology</p>alshukri@mail.ruAcademician I.P. Pavlov First St Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation1503201771101427042017Copyright © 2017, Kurnakov A.M., Borovets S.Y., Al-Shukri S.K.2017<p>The current study presents the results of analysis of 121 patients with suspected prostate cancer, conducted at the Urology department of the Railways hospital in the period from 2014 to 2015. The comprehensive assessment of Doppler indicators and laboratory factors in the diagnosis of prostate cancer was performed to identify their individual importance. After receiving the results of histological studies the comparative analysis of the zonal flow was carried out depending on the morphological diagnosis in the patient groups and between areas with tumor and without it. During dopplerography peak, systolic and average blood flow velocity were significantly higher in tumor areas. Using complete analysis of laboratory and instrumental parameters we achieved mathematical model allowing to increase the efficiency of differential diagnosis of prostate diseases for patients with prostate biopsy.</p>differential diagnosis of diseases of the prostateDopplerprostate biopsyдифференциальная диагностиказаболевания предстательной железыдоплерографиябиопсия предстательной железы[1. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower rinary tract symptoms suggestive of benign prostatic hyperplasia in primary care: the Triumph project. Eur Urol. 2002;42:323-328. doi: 10.1016/S0302-2838(02)00354-8.][2. Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х., Пушкарь Д.Ю. Симптомы нижних мочевых путей у мужчин Северо-Западного региона Российской Федерации: анализ результатов популяционного исследования // Урологические ведомости. – 2016. – Т. 6. – № 1. – С. 5–9. [Korneev IA, Alekseeva TA, Al’-Shukri SKh, Pushkar’ DYu. Lower urinary tract symptoms in male population of the Russian Federation North-Western Region: analysis of population study results. Urologicheskie vedomosti. 2016;6(1)5-9. (In Russ.)]. doi: 10.17816/uroved615-9.][3. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140. doi: 10.1016/j.eururo.2013.03.004.][4. Кузьмин И.В. Оценка качества жизни у больных с гиперактивностью мочевого пузыря // Нефрология. – 2006. – Т. 10. – № 4. – С. 93–97. [Kuz’min IV. Otsenka kachestva zhizni u bol’nykh s giperaktivnost’yu mochevogo puzyrya. Nefrologiya. 2006;10(4):93-97. (In Russ.)]][5. Зайцев В.Г., Скворцов В.В. Простатический специфический антиген (ПСА) в диагностике рака предстательной железы //Поликлиника. – 2012. – № 3–4. – С. 55–58. [Zaytsev VG, Skvortsov VV. Prostaticheskiy spetsificheskiy antigen (PSA) v diagnostike raka predstatel’noy zhelezy. Poliklinika. 2012;(3-4):55-58. (In Russ.)]][6. Каприн А.Д., Аполихин О.И., Сивков А.В., и др. Анализ уронефрологической летальности и смертности в Российской Федерации за 2003–2013 гг. // Экспериментальная и клиническая урология. – 2015. – № 2. – С. 4–13. [Kaprin AD, Apolikhin OI, Sivkov AV, et al. Analiz uronefrologicheskoy letal’nosti i smertnosti v rossiyskoy Federatsii za 2003–2013 gg. Eksperimental’naya i klinicheskaya urologiya. 2015;(2):4-13. (In Russ.)]][7. Понкратов С.В., Хейфец В.Х., Каган О.Ф. Диагностическая ценность простатспецифического антигена с учетом возраста пациентов // Урологические ведомости. – 2016. – Т. 6. – № 3. – С. 30–39. [Ponkratov SV, Kheyfets VKh, Kagan OF. Diagnostic value of prostate-specific antigen according to age patients. Urologicheskie vedomosti. 2016;6(3):30-39. (In Russ.)]. doi: 10.17816/uroved6330-39.][8. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 году. – М.: Минздрав России, 2014. – 209 с. [Kaprin AD, Starinskiy VV, Petrova GV. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2013 godu. Moscow: Minzdrav Rossii; 2014. P. 209. (In Russ.)]][9. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002;167(3):1363-1366. doi: 10.1016/S0022-5347(05)65301-3.][10. Носов А.К. Раннее выявление рака предстательной железы //Практическая онкология. – 2010. – Т. 11. – № 2. – С. 74–80. [Nosov AK. Rannee vyyavlenie raka predstatel’noy zhelezy //Prakticheskaya onkologiya. 2010;11(2):74-80. (In Russ.)]][11. Chen FK, de Castro Abreu AL, Palmer SL. Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art. J Nucl Med. 2016;57:13-18. doi: 10.1016/j.amjmed.2015.11.001.][1. 12.Del Rosso A, Di Pierro ED, Masciovecchio S, et al. Does transrectal color Doppler ultrasound improve the diagnosis of prostate cancer? Arch Ital Urol Androl. 2012;84(1):22-25.][12. Zhang X, Li G, Hu L, et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Med Oncol. 2014;31(12):297. doi: 10.1007/s12032-014-0297-9.]